Global Rhabdomyolysis Treatment Market, By Cause (Viral Infections, Bacterial infections, Polymyositis, Dermatomyositis, Others), Treatment (Intravenous (IV) Fluids, Mannitol, Loop Diuretics, Dialysis, Surgery, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Clinics, Hospitals, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Rhabdomyolysis treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 3.90% in the above-mentioned research forecast period. Rising geriatric population and increasing number of viral infections may drive the market growth.
Moreover, surge in awareness about disease cause and treatment and technological advancements also boost up the market growth. Moreover, increasing research and development and rising healthcare expenditure act as opportunities for the market growth. But, sometimes adverse effect related to the drugs, strict regulatory framework and lack of proper diagnostics facilities for diseases may hamper the rhabdomyolysis treatment market.
Rhabdomyolysis refers to the medical condition characterized by the rapid dissolution of injured or damaged skeletal muscle. Due to disruption of skeletal muscle integrity the direct release of intracellular components including creatine kinase, aldolase, muscle components, lactate dehydrogenase and electrolytes takes place directly into the blood stream and extracellular space. The Rhabdomyolysis condition ranges from an asymptomatic illness represented by the elevation in the creatine kinase level to a life-threatening condition recognized by the higher electrolyte imbalance, rise in the level of creatine kinase, acute renal failure and disseminated intravascular coagulation. The major cause associated with Rhabdomyolysis includes traumatic injury, moreover excessive consumption of toxins, drugs, infections, muscle ischemia, metabolic disorders, genetic disorders, exertion or prolonged bed-rest can also lead to Rhabdomyolysis. The patients suffers from Rhabdomyolysis relies on several treatment options including administration of intravenous (IV) fluids, mannitol, loop diuretics, dialysis treatment and surgery among others.
Rhabdomyolysis has been reported to adversely affect the males, obese people and people above the age of 60 years are more likely to develop this disease.
As per the data provided by the WHO the worldwide geriatric population over the age of 60 years expected to double from 12% to 22% in between the 2015 to 2050. This has been reported that patients above the age of 65 years have five time higher level of creatine kinase as compared to normal people, which is responsible for enhancing the cases of Rhabdomyolysis and hence expected to provide market with the lucrative growth. It is also estimated that Rhabdomyolysis treatment market is growing with the CAGR of 3.90% in 2020.
This Rhabdomyolysis treatment market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Rhabdomyolysis Treatment Market Scope and Market Size
Rhabdomyolysis treatment market is segmented on the basis of cause, treatment, route of administration, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of cause, the Rhabdomyolysis treatment market is segmented into viral infections, bacterial infections, polymyositis, dermatomyositis, others.
- On the basis of treatment, the Rhabdomyolysis treatment market is segmented into intravenous (IV) fluids, mannitol, loop diuretics, dialysis, surgery, others. Loop diuretics is further sub-segmented into furosemide, bumetanide, torsemide and others.
- On the basis of route of administration, the Rhabdomyolysis treatment market is segmented into oral, parenteral, others.
- On the basis of end-users, the Rhabdomyolysis treatment market is segmented into clinics, hospitals, homecare, others.
- On the basis of distribution channel, the Rhabdomyolysis treatment market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy, others.
Rhabdomyolysis Treatment Market Country Level Analysis
Rhabdomyolysis treatment market is analysed and market size information is provided by country, cause, treatment, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Rhabdomyolysis treatment market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America accounts the largest market share due to the technological advancement for appropriate disease diagnosis and increasing healthcare expenditure. Middle East & Africa accounts the second largest market share due to high prevalence of infections in developing countries. Asia-Pacific is expected to account for the largest market share over coming years for the Rhabdomyolysis treatment market due to increase in per capita income, improvement of healthcare infrastructure and urge in awareness towards better treatment options.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Rhabdomyolysis treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Rhabdomyolysis Treatment Market Share Analysis
Rhabdomyolysis treatment market competitive landscape provides details by competitor details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to Rhabdomyolysis treatment market.
The major players covered in the Rhabdomyolysis treatment market are Pfizer Inc., Atom Pharma, Sanofi, Ipca Laboratories Ltd., R.W. Unwin & Co. Ltd., Fresenius Kabi (Singapore) Pte Ltd, Reine Life Science, Actiza Pharmaceutical Private Limited, AdvaCare Pharma, Roquette Frères, Kerry, NIKSAN PHARMACEUTICAL, Teva Pharmaceuticals USA, Inc., ANGLE BIO PHARMA, Vibcare Pharma Pvt. Ltd., Cipla, Nikkiso Co., Ltd. among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.